Stocks
Invitae CorporationNVTA
HealthcareBiotechnology
A clinical genetics company that provides genetic testing services and digital health solutions for hereditary diseases, oncology, and rare conditions. It operates a laboratory network and sells tests to healthcare providers, patients, and pharmaceutical partners. Investors track the company for its role in the growing precision medicine market, though it has faced financial restructuring and bankruptcy proceedings.
Congressional Interest in Invitae Corporation (NVTA)
4 members of Congress have disclosed 6 trades in Invitae Corporation (NVTA), a Healthcare company. The buy/sell breakdown shows 3 purchases versus 3 sales. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
6
Unique Politicians
4
Buys
3
Sells
3
Who in Congress Is Trading NVTA?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2022-08-04 | Diana Harshbarger | sell | $1K-$15K |
| 2018-04-04 | Jared Polis | sell | $50K-$100K |
| 2018-04-04 | Jared Polis | buy | $50K-$100K |
| 2017-12-05 | Doug Lamborn | buy | $15K-$50K |
| 2017-12-04 | Doug Lamborn | buy | $1K-$15K |
| 2017-04-17 | MICHAEL T. MCCAUL | sell | $1K-$15K |